{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:09:24Z","timestamp":1789135764143,"version":"build-2803163510"},"reference-count":14,"publisher":"American Chemical Society (ACS)","issue":"36","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010023","name":"Natural Science Research of Jiangsu Higher Education Institutions of China","doi-asserted-by":"publisher","award":["25KJA350001"],"award-info":[{"award-number":["25KJA350001"]}],"id":[{"id":"10.13039\/501100010023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["KYCX25_2195"],"award-info":[{"award-number":["KYCX25_2195"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008868","name":"Jiangsu Provincial Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008868","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Province Innovation Center for Brain-Inspired Intelligence Technology","award":["BM2024001"],"award-info":[{"award-number":["BM2024001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chiral \u03b4-caprolactam constitutes the key pharmacophore of Calcitonin gene-related peptide receptor antagonists such as ubrogepant and atogepant, and its synthesis is quite challenging. Herein, we report a novel, robust, and potentially scalable asymmetric synthesis strategy for chiral \u03b4-caprolactam. The \u03b4-caprolactam scaffold is first constructed via a one-pot process, followed by sequential installation of three stereocenters through crystallization-induced dynamic kinetic resolution and catalytic hydrogenation. This protocol offers distinct advantages, including the absence of enzymatic catalysis and column chromatography.<\/jats:p>","DOI":"10.1021\/acs.joc.6c01034","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:39:00Z","timestamp":1785854340000},"page":"12457-12461","source":"Crossref","is-referenced-by-count":0,"title":["Asymmetric Synthesis\nof Chiral \u03b4-Caprolactams:\nAccess to a Key Intermediate of Ubrogepant"],"prefix":"10.1021","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0428-4790","authenticated-orcid":true,"given":"Qingyuan","family":"Shi","sequence":"first","affiliation":[{"name":"Nanjing Medical University , , ,","place":["Nanjing, China, 211166"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanjing Medical University , , ,","place":["Nanjing, China, 211166"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Nanjing Medical University , , ,","place":["Nanjing, China, 211166"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhu","sequence":"additional","affiliation":[{"name":"Nanjing Medical University , , ,","place":["Nanjing, China, 211166"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Nanjing Medical University , , ,","place":["Nanjing, China, 211166"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyi","family":"Xing","sequence":"additional","affiliation":[{"name":"Nanjing Medical University , , ,","place":["Nanjing, China, 211166"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[{"name":"Nanjing Medical University , , ,","place":["Nanjing, China, 211166"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyin","family":"Chen","sequence":"additional","affiliation":[{"name":"Nanjing Medical University , , ,","place":["Nanjing, China, 211166"]},{"name":"Jiangsu Province Innovation Center for Brain-Inspired Intelligence Technology , ,","place":["Nanjing, China, 211166"]},{"name":"Innovation Center of Suzhou Nanjing Medical University , ,","place":["Suzhou, China, 215100"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"11","key":"2026091109112753200_cit1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41582-024-01011-4","article-title":"Pituitary adenylate\ncyclase-activating polypeptide signalling as a therapeutic target\nin migraine","volume":"20","author":"Ashina","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"2026091109112753200_cit2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target\nof new migraine therapies - successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"23","key":"2026091109112753200_cit3a","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the\nTreatment of Migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"2026091109112753200_cit3b","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41582-025-01107-5","article-title":"Ubrogepant alleviates migraine premonitory symptoms","volume":"21","author":"Wood","year":"2025","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"2026091109112753200_cit3c","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"ADVANCE\nStudy Group. Atogepant for the Preventive Treatment of Migraine","volume":"385","author":"Ailani","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"2026091109112753200_cit3d","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an Oral Calcitonin Gene-Related Peptide\nReceptor Antagonist, for Migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N. Engl.\nJ. Med."},{"issue":"10268","key":"2026091109112753200_cit3e","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine:\na phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2026091109112753200_cit3f","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","article-title":"Safety,\ntolerability, and efficacy of zavegepant 10 mg nasal spray for the\nacute treatment of migraine in the USA: a phase 3, double-blind, randomised,\nplacebo-controlled multicentre trial","volume":"22","author":"Lipton","year":"2023","journal-title":"Lancet\nNeurol."},{"key":"2026091109112753200_cit4","unstructured":"Merck SharpDohme LLC.\n          \n          Process For\nMaking cgrp Receptor Antagonists. WO\n2013169348 A1, 2013."},{"issue":"11","key":"2026091109112753200_cit5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1021\/acs.oprd.7b00293","article-title":"Practical\nAsymmetric Synthesis of a Calcitonin Gene-Related Peptide (CGRP) Receptor\nAntagonist Ubrogepant","volume":"21","author":"Yasuda","year":"2017","journal-title":"Org. Process Res. Dev."},{"issue":"10","key":"2026091109112753200_cit6","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1021\/acs.oprd.6b00207","article-title":"Crystallization-Induced\nDynamic Resolution toward the Synthesis of\n(S)-7-Amino-5H,7H-dibenzo[b, d]-azepin-6-one:\nAn Important Scaffold for \u03b3-Secretase Inhibitors","volume":"20","author":"Karmakar","year":"2016","journal-title":"Org. Process Res. Dev."},{"issue":"12","key":"2026091109112753200_cit7","doi-asserted-by":"publisher","first-page":"9359","DOI":"10.1039\/D5RA00035A","article-title":"A practical one-pot synthesis of\ndehydroalanine esters","volume":"15","author":"Shi","year":"2025","journal-title":"RSC Adv."},{"issue":"7","key":"2026091109112753200_cit8","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1021\/cr0406864","article-title":"Crystallization-induced\ndiastereomer transformations","volume":"106","author":"Brands","year":"2006","journal-title":"Chem. Rev."},{"issue":"22","key":"2026091109112753200_cit9","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.1021\/jo101704b","article-title":"Asymmetric\nsynthesis of telcagepant,\na CGRP receptor antagonist for the treatment of migraine","volume":"75","author":"Xu","year":"2010","journal-title":"J. Org. Chem."}],"container-title":["The Journal of Organic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.joc.6c01034","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/joceah\/article-pdf\/91\/36\/12457\/66369885\/acs.joc.6c01034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/joceah\/article-pdf\/91\/36\/12457\/66369885\/acs.joc.6c01034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:32:42Z","timestamp":1789133562000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/joceah\/article\/91\/36\/12457\/5240756\/Asymmetric-Synthesis-of-Chiral-Caprolactams-Access"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":14,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2026,8,3]]},"published-print":{"date-parts":[[2026,9,11]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.joc.6c01034","relation":{},"ISSN":["0022-3263","1520-6904"],"issn-type":[{"value":"0022-3263","type":"print"},{"value":"1520-6904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}